लोड हो रहा है...

No Benefit of Concomitant 5-Aminosalicylates in Patients with Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data from Clinical Trials

BACKGROUND AND AIMS: 5-aminosalicylates (5-ASA) are frequently continued in patients with moderate-severe ulcerative colitis (UC), even after escalation to biologic agents, without evaluation of the benefit of this approach. We conducted an individual participant data (IPD) pooled analysis of trials...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Am J Gastroenterol
मुख्य लेखकों: Singh, Siddharth, Proudfoot, James A., Dulai, Parambir S., Jairath, Vipul, Fumery, Mathurin, Xu, Ronghui, Feagan, Brian G., Sandborn, William J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2018
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7107271/
https://ncbi.nlm.nih.gov/pubmed/29925913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41395-018-0144-2
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!